Thrivent Financial for Lutherans Cuts Stock Position in GE HealthCare Technologies Inc. $GEHC

Thrivent Financial for Lutherans lessened its stake in GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 11.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 64,401 shares of the company’s stock after selling 7,926 shares during the period. Thrivent Financial for Lutherans’ holdings in GE HealthCare Technologies were worth $5,282,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its stake in GE HealthCare Technologies by 0.5% in the fourth quarter. Vanguard Group Inc. now owns 52,275,767 shares of the company’s stock valued at $4,287,658,000 after purchasing an additional 267,058 shares during the last quarter. Dodge & Cox grew its stake in GE HealthCare Technologies by 16.8% in the third quarter. Dodge & Cox now owns 27,517,311 shares of the company’s stock valued at $2,066,550,000 after purchasing an additional 3,949,361 shares during the last quarter. Capital Research Global Investors grew its stake in GE HealthCare Technologies by 25.0% in the third quarter. Capital Research Global Investors now owns 24,972,556 shares of the company’s stock valued at $1,875,400,000 after purchasing an additional 4,998,154 shares during the last quarter. Hotchkis & Wiley Capital Management LLC grew its stake in GE HealthCare Technologies by 17.1% in the third quarter. Hotchkis & Wiley Capital Management LLC now owns 8,432,374 shares of the company’s stock valued at $633,271,000 after purchasing an additional 1,232,828 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its stake in GE HealthCare Technologies by 8.9% in the third quarter. Dimensional Fund Advisors LP now owns 5,362,717 shares of the company’s stock valued at $402,647,000 after purchasing an additional 438,439 shares during the last quarter. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Insider Buying and Selling

In related news, Director Watkin Phoebe L. Yang purchased 1,000 shares of the firm’s stock in a transaction on Friday, May 8th. The stock was bought at an average cost of $63.01 per share, with a total value of $63,010.00. Following the completion of the acquisition, the director owned 13,702 shares of the company’s stock, valued at $863,363.02. The trade was a 7.87% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Peter J. Arduini purchased 4,169 shares of the firm’s stock in a transaction on Thursday, April 30th. The stock was bought at an average cost of $59.92 per share, with a total value of $249,806.48. Following the completion of the acquisition, the chief executive officer directly owned 259,424 shares of the company’s stock, valued at $15,544,686.08. This trade represents a 1.63% increase in their position. The SEC filing for this purchase provides additional information. Insiders acquired a total of 11,847 shares of company stock valued at $719,555 in the last three months. 0.36% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of brokerages have recently weighed in on GEHC. BTIG Research dropped their price target on GE HealthCare Technologies from $85.00 to $80.00 and set a “buy” rating on the stock in a research note on Wednesday, April 29th. BNP Paribas Exane dropped their price target on GE HealthCare Technologies from $95.00 to $88.00 in a research note on Friday, May 1st. Morgan Stanley boosted their price target on GE HealthCare Technologies from $80.00 to $85.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 4th. Wells Fargo & Company dropped their price target on GE HealthCare Technologies from $97.00 to $75.00 and set an “overweight” rating on the stock in a research note on Thursday, April 30th. Finally, Oppenheimer restated an “outperform” rating and set a $85.00 price target on shares of GE HealthCare Technologies in a research note on Thursday, April 30th. Nine analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat, GE HealthCare Technologies currently has an average rating of “Moderate Buy” and an average price target of $80.21.

GE HealthCare Technologies Trading Up 0.1%

GE HealthCare Technologies stock opened at $64.33 on Friday. The company has a quick ratio of 0.95, a current ratio of 1.22 and a debt-to-equity ratio of 0.95. GE HealthCare Technologies Inc. has a 52 week low of $58.75 and a 52 week high of $89.77. The company has a market capitalization of $29.26 billion, a price-to-earnings ratio of 15.39, a price-to-earnings-growth ratio of 1.45 and a beta of 0.74. The stock has a 50-day moving average price of $68.62 and a 200 day moving average price of $76.33.

GE HealthCare Technologies (NASDAQ:GEHC) last released its earnings results on Wednesday, April 29th. The company reported $0.99 EPS for the quarter, missing analysts’ consensus estimates of $1.07 by ($0.08). GE HealthCare Technologies had a return on equity of 20.46% and a net margin of 9.10%.The firm had revenue of $5.13 billion for the quarter, compared to analyst estimates of $5.04 billion. During the same period last year, the firm earned $1.01 EPS. The company’s revenue for the quarter was up 7.4% compared to the same quarter last year. GE HealthCare Technologies has set its FY 2026 guidance at 4.800-5.000 EPS. Sell-side analysts anticipate that GE HealthCare Technologies Inc. will post 4.89 EPS for the current year.

GE HealthCare Technologies Profile

GE HealthCare Technologies (NASDAQ: GEHC) is a global medical technology and diagnostics company that develops, manufactures and markets a broad range of products and services for healthcare providers. Its portfolio centers on diagnostic imaging systems, including MRI, CT, PET and X-ray modalities, as well as ultrasound equipment. The company also supplies patient monitoring and anesthesia delivery systems, interventional and surgical imaging solutions, and molecular imaging technologies used in both clinical care and research settings.

In addition to hardware, GE HealthCare offers software, analytics and lifecycle services aimed at improving clinical workflows and equipment uptime.